BUSINESS
Teijin to Receive US$5 Million Milestone as Narcolepsy Drug Enters European PI
Teijin Pharma said on November 27 that it will receive a US$5 million milestone payment from French drug maker Bioprojet after the companies’ narcolepsy treatment candidate entered PI clinical testing in Europe.The payment is based on the exclusive global license…
To read the full story
Related Article
- Teijin Out-Licenses Narcolepsy Drug to France’s Bioprojet
April 11, 2024
BUSINESS
- Sanofi Files Dupixent for CSU in Children Aged 2-11 in Japan
December 26, 2025
- Enhertu Wins 5th China Indication in HER2-Low/Ultralow Breast Cancer
December 26, 2025
- SymBio Bags Rights to Develop Antiviral Brincidofovir for Alzheimer’s
December 26, 2025
- Dayvigo Wins Triple Crown in November HP Promotion List: Intage
December 26, 2025
- Pharma Hails End to “Spillover” Rule, Vows to Keep Fighting Off-Year Cuts
December 25, 2025
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…





